| Dr Michael D Peters, MD | |
|
9825 Hospital Dr, Suite Ll-10, Maple Grove, MN 55369-4479 | |
| (612) 339-2836 | |
| (763) 420-3376 |
| Full Name | Dr Michael D Peters |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 28 Years |
| Location | 9825 Hospital Dr, Maple Grove, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194775429 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YS0123X | Otolaryngology - Facial Plastic Surgery | 44049 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mcleod Loris Hospital | Loris, SC | Hospital |
| Novant Health Brunswick Medical Center | Supply, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coastal Carolina Ent Do Pa | 8325082498 | 5 |
| Coastal Carolina Ent Do Pa | 8325082498 | 5 |
News Archive
Sutter Health will pay $575 million to settle a closely watched antitrust case filed by California Attorney General Xavier Becerra, whose office had accused the nonprofit health care giant of using its market dominance in Northern California to illegally drive up prices.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
A research work carried out at the Laboratory of Forensic Anthropology of the University of Granada will speed up the identification of more than 2,000 missing persons in Kosovo during former Yugoslavia war, besides developing a new forensic technique based on the study of ribs and pubis, which will be very useful for the identification of persons in armed conflicts. This work, pioneer all over the world, has involved the study of one of the greatest forensic samples never before analysed.
Medical device company Vertos Medical Inc. has announced that one-year post-study follow-up data on its mild procedure for lumbar spinal stenosis (LSS) have been published in the peer-reviewed journal Pain Practice.
› Verified 5 days ago
| Entity Name | Coastal Carolina Ent Do Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386989028 PECOS PAC ID: 8325082498 Enrollment ID: O20130219000386 |
News Archive
Sutter Health will pay $575 million to settle a closely watched antitrust case filed by California Attorney General Xavier Becerra, whose office had accused the nonprofit health care giant of using its market dominance in Northern California to illegally drive up prices.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
A research work carried out at the Laboratory of Forensic Anthropology of the University of Granada will speed up the identification of more than 2,000 missing persons in Kosovo during former Yugoslavia war, besides developing a new forensic technique based on the study of ribs and pubis, which will be very useful for the identification of persons in armed conflicts. This work, pioneer all over the world, has involved the study of one of the greatest forensic samples never before analysed.
Medical device company Vertos Medical Inc. has announced that one-year post-study follow-up data on its mild procedure for lumbar spinal stenosis (LSS) have been published in the peer-reviewed journal Pain Practice.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael D Peters, MD 9825 Hospital Dr, Suite Ll-10, Maple Grove, MN 55369-4479 Ph: (612) 339-2836 | Dr Michael D Peters, MD 9825 Hospital Dr, Suite Ll-10, Maple Grove, MN 55369-4479 Ph: (612) 339-2836 |
News Archive
Sutter Health will pay $575 million to settle a closely watched antitrust case filed by California Attorney General Xavier Becerra, whose office had accused the nonprofit health care giant of using its market dominance in Northern California to illegally drive up prices.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
A research work carried out at the Laboratory of Forensic Anthropology of the University of Granada will speed up the identification of more than 2,000 missing persons in Kosovo during former Yugoslavia war, besides developing a new forensic technique based on the study of ribs and pubis, which will be very useful for the identification of persons in armed conflicts. This work, pioneer all over the world, has involved the study of one of the greatest forensic samples never before analysed.
Medical device company Vertos Medical Inc. has announced that one-year post-study follow-up data on its mild procedure for lumbar spinal stenosis (LSS) have been published in the peer-reviewed journal Pain Practice.
› Verified 5 days ago
Jonathan Dell, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 18901 62nd Ave N, Maple Grove, MN 55311 Phone: 917-780-8719 |